Elsevier, Journal of Dermatological Science, 2(78), p. 149-151
DOI: 10.1016/j.jdermsci.2015.01.005
Full text: Unavailable
Erythrodermic psoriasis (EP) is one of the most severe cutaneous conditions which may lead to serious morbidity and even mortality. This condition is often difficult to manage and, due to its rarity (estimated prevalence 1–2.25% of psoriatic patients) there is a lack of high-quality medical literature examining treatment options [1].